Afisarea articolelor 1-1(1) pentru cuvîntul-cheie "Eltrombopag"
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia |
12, 3, 45, 6, 12, Cooper Nichola7, 8, 8, 8, 9, 10, 11, Bussel James Bruce12, 13 |
1 Medical University of Lodz, 2 Copernicus Memorial Hospital, Lodz, 4 La Fe University and Polytechnic Hospital, Valencia, 6 Institute of Oncology, 7 Imperial College Healthcare National Health Service Trust, London, 8 Union Chimique Belge (UCB) Pharma, Monheim-am-Rhein, 9 UCB Pharma, Raleigh, 11 PTx Solutions Ltd., London, 12 Weill Cornell Medicine, New York, 13 University Hospital of Wales, Cardiff |
Blood Advances |
Nr. 4(17) / 2020 / ISSN 2473-9537 |
Disponibil online 15 March, 2021. Descarcări-0. Vizualizări-496 |
1-1 of 1